Table 1.

Estimated OR and 95%CI of pairwise meta-analysis for hematologic toxicity events in advanced or metastatic pancreatic cancer patients.

		Toxicity events		Pairwise meta-analysis
Included studies	Comparisons	Treatment1	Treatment2	OR (95%CI)
Hematologic (all grades)
Anemia
1 study	A vs. B	55/308	27/305	2.24 (1.37–3.66)
1 study	A vs. C	36/80	39/80	0.86 (0.46–1.60)
1 study	A vs. D	50/52	20/50	37.50 (8.18–171.87)
1 study	A vs. G	97/342	97/331	0.96 (0.68–1.33)
Neutropenia
1 study	A vs. B	55/308	73/305	0.69 (0.47–1.02)
1 study	A vs. C	35/80	37/80	0.90 (0.40–1.69)
1 study	A vs. D	48/52	32/50	6.75 (2.09–21.79)
1 study	A vs. G	63/342	73/331	0.80 (0.55–1.16)
Thrombocytopenia
1 study	A vs. B	37/308	49/305	0.71 (0.45–1.13)
1 study	A vs. C	37/80	49/80	0.54 (0.29–1.02)
1 study	A vs. D	38/52	40/50	0.68 (0.27–1.71)
1 study	A vs. G	66/342	78/331	0.78 (0.54–1.12)
Hematologic (grade≥3)
Anemia
1 study	A vs. B	9/308	3/305	3.03 (0.81–11.30)
1 study	A vs. C	9/80	18/80	0.44 (0.18–1.04)
1 study	A vs. D	15/52	2/50	9.73 (2.09–45.22)
1 study	A vs. E	8/263	5/277	1.71 (0.55–5.29)
1 study	A vs. G	16/342	20/331	0.76 (0.39–1.50)
Neutropenia
1 study	A vs. B	34/308	52/305	0.60 (0.38–0.96)
1 study	A vs. C	24/80	26/80	0.89 (0.46–1.74)
1 study	A vs. D	29/52	26/50	1.16 (0.53–2.54)
1 study	A vs. E	29/263	33/277	0.92 (0.54–1.56)
1 study	A vs. G	30/342	40/331	0.70 (0.42–1.15)
Thrombocytopenia
1 study	A vs. B	9/308	15/305	0.58 (0.25–1.35)
1 study	A vs. C	13/80	12/80	1.10 (0.47–2.58)
1 study	A vs. D	12/52	6/50	2.20 (0.76–6.41)
1 study	A vs. E	12/263	12/277	1.06 (0.47–2.39)
1 study	A vs. G	12/342	15/331	0.77 (0.35–1.66)

Notes: OR = odds ratio; 95%CI = 95% confidence intervals; A = Gemcitabine+Placebo; B = Gemcitabine+Axitinib; C = Gemcitabine+Trametinib; D = Gemcitabine+Sorafenib; E = Gemcitabine+Bevacizumab; G = Gemcitabine+Tipifarnib.